BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

BridgeBio Pharma (NASDAQ:BBIO) had its price target upped by equities researchers at JPMorgan Chase & Co. from $100.00 to $111.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 32.73% from the stock’s previous close.

Several other brokerages have also recently issued reports on BBIO. Bank of America increased their target price on BridgeBio Pharma from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday. Citigroup raised their price objective on BridgeBio Pharma from $82.00 to $93.00 and gave the company a “neutral” rating in a research report on Thursday, July 16th. Raymond James Financial lowered shares of BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 26th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of BridgeBio Pharma in a research report on Friday, May 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $110.00 price objective on shares of BridgeBio Pharma in a research note on Tuesday. Twenty equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $100.42.

BridgeBio Pharma Stock Down 0.1%

Shares of BBIO stock traded down $0.07 on Wednesday, hitting $83.63. The stock had a trading volume of 87,369 shares, compared to its average volume of 2,986,128. BridgeBio Pharma has a one year low of $46.81 and a one year high of $93.42. The business has a 50 day moving average price of $76.47 and a 200 day moving average price of $73.07. The company has a market cap of $16.35 billion, a PE ratio of -23.41 and a beta of 0.96.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Monday, August 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The business had revenue of $243.68 million for the quarter, compared to the consensus estimate of $220.91 million. BridgeBio Pharma’s quarterly revenue was up 120.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.95) EPS. Equities research analysts expect that BridgeBio Pharma will post -2.31 EPS for the current year.

Insider Activity

In related news, Director Hannah Valantine sold 2,196 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $68.57, for a total value of $150,579.72. Following the sale, the director owned 9,259 shares in the company, valued at $634,889.63. This represents a 19.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jennifer E. Cook sold 148,589 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $88.54, for a total transaction of $13,156,070.06. Following the completion of the transaction, the director owned 8,383 shares in the company, valued at approximately $742,230.82. This trade represents a 94.66% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 392,117 shares of company stock valued at $29,934,700. 14.23% of the stock is owned by insiders.

Institutional Trading of BridgeBio Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in BBIO. Silvant Capital Management LLC purchased a new stake in BridgeBio Pharma in the second quarter valued at $28,000. Allworth Financial LP purchased a new position in shares of BridgeBio Pharma during the 2nd quarter valued at about $31,000. Harvest Fund Management Co. Ltd purchased a new position in shares of BridgeBio Pharma during the 3rd quarter valued at about $34,000. Jones Financial Companies Lllp acquired a new position in shares of BridgeBio Pharma in the 1st quarter valued at about $35,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after buying an additional 245 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

Key Stories Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Second-quarter revenue rose 120.4% year over year to $243.68 million, beating the $220.91 million consensus estimate. Growth was led by Attruby, whose U.S. net sales reportedly increased 311%, while ex-U.S. Beyonttra royalties also improved. BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
• Positive Sentiment: Management reaffirmed guidance for more than $1 billion in 2026 global Attruby and Beyonttra sales and expects three product launches by mid-2027. A $1 billion preferred-equity financing also strengthens the balance sheet and supports commercial and pipeline investment. BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months
• Positive Sentiment: Analysts raised their valuation targets: Piper Sandler to $115, TD Cowen to $110, Bank of America to $104, and Wells Fargo to $102, with each maintaining a positive rating. Morgan Stanley made a smaller reduction to $97 but retained its overweight rating.
• Neutral Sentiment: BridgeBio was highlighted among biotech companies with potentially important second-half 2026 catalysts, including regulatory decisions and late-stage clinical readouts. 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
• Negative Sentiment: Adjusted quarterly loss was $0.78 per share, worse than the approximately $0.58–$0.64 analyst expectations, although it improved from a $0.95 loss a year earlier. The earnings shortfall is likely the main source of near-term selling pressure.
• Negative Sentiment: BridgeBio granted restricted stock units covering 66,705 shares to 56 new employees. The routine hiring-related awards may create limited shareholder dilution. BridgeBio Pharma Reports Inducement Grants

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.